Lifeng Fu

Years Active: 2020-2021
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Yu Bai, Fei Ye, Yong Feng, Hanyi Liao, Hao Song, Jianxun Qi, George Fu Gao, Wenjie Tan, Lifeng Fu, Yi Shi
Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal transduction and targeted therapy 6 (1) (2021)
Lifeng Fu, Fei Ye, Yong Feng, Feng Yu, Qisheng Wang, Yan Wu, Cheng Zhao, Huan Sun, Baoying Huang, Peihua Niu, Hao Song, Yi Shi, Xuebing Li, Wenjie Tan, Jianxun Qi, George Fu Gao
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature communications 11 (1) (2020)
Yu-Hai Bi, Xiufan Liu, Shanqin Li, Guanghua Fu, Tao Jin, Cheng Zhang, Yongchun Yang, Zhenghai Ma, Wen-Xia Tian, Jida Li, Shuqi Xiao, Liqiang Li, Renfu Yin, Yi Zhang, Lixin Wang, Yantao Qin, Zhongzi Yao, Fanyu Meng, Dongfang Hu, Delong Li, Gary Wong, Fei Liu, Na Lv, Liang Wang, Lifeng Fu, Yang Yang, Yun Peng, Jinmin Ma, Kirill Sharshov, Alexander Shestopalov, Marina A Gulyaeva, George Fu Gao, Jianjun Chen, Yi Shi, William J Liu, Dong Chu, Yu Huang, Yingxia Liu, Lei Liu, Wenjun Liu, Quanjiao Chen, Wei-Feng Shi
Dominant subtype switch in avian influenza viruses during 2016-2019 in China. Nature communications 11 (1) (2020)

Lifeng Fu.css-eqlu8i{font-size:small;padding-left:4px;}